Sarcoma (Jan 2017)

Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma

  • Thomas Cash,
  • Hong Yin,
  • Courtney McCracken,
  • Zhi Geng,
  • Steven G. DuBois,
  • Bahig M. Shehata,
  • Thomas A. Olson,
  • Howard M. Katzenstein,
  • Cynthia Wetmore

DOI
https://doi.org/10.1155/2017/8758623
Journal volume & issue
Vol. 2017

Abstract

Read online

Background. Ezrin is a membrane-cytoskeleton linker protein that has been associated with metastasis and poor outcomes in osteosarcoma and high-grade soft tissue sarcomas. The prognostic value of ezrin expression in Ewing sarcoma is unknown. Methods. The relationship between ezrin expression and outcome was analyzed in a cohort of 53 newly diagnosed Ewing sarcoma patients treated between 2000 and 2011. The intensity and proportion of cells with ezrin immunoreactivity were assessed in diagnostic tumor tissue using a semiquantitative scoring system to yield intensity and positivity scores for each tumor. Results. Ezrin expression was detected in 72% (38/53) of tumor samples. The proportion of patients with metastatic disease was equal in the positive and negative ezrin expression groups. There was no significant difference in the 5-year event-free survival (EFS) between patients with positive versus negative ezrin expression. Patients whose tumor sample showed high ezrin intensity had significantly better 5-year EFS when compared to patients with low/no ezrin intensity (78% versus 55%; P=0.03). Conclusions. Ezrin expression can be detected in the majority of Ewing sarcoma tumor samples. Intense ezrin expression may be correlated with a favorable outcome; however further investigation with a larger cohort is needed to validate this finding.